>
Switch to:

OncoCyte PS Ratio

: 65.38 (As of Today)
View and export this data going back to 2015. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, OncoCyte's share price is $3.40. OncoCyte's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 was $0.05. Hence, OncoCyte's PS Ratio for today is 65.38.

Good Sign:

OncoCyte Corp stock PS Ratio (=65.38) is close to 2-year low of 63.46

The historical rank and industry rank for OncoCyte's PS Ratio or its related term are showing as below:

NAS:OCX' s PS Ratio Range Over the Past 10 Years
Min: 63.45   Med: 148.5   Max: 1685
Current: 65.36

63.45
1685

During the past 8 years, OncoCyte's highest PS Ratio was 1685.00. The lowest was 63.45. And the median was 148.50.

NAS:OCX's PS Ratio is ranked lower than
99.99% of the 251 Companies
in the Biotechnology industry.

( Industry Median: 14.74 vs. NAS:OCX: 65.36 )

OncoCyte's Revenue per Sharefor the three months ended in Jun. 2021 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 was $0.05.

During the past 12 months, the average Revenue per Share Growth Rate of OncoCyte was 2500.00% per year.

Back to Basics: PS Ratio


OncoCyte PS Ratio Historical Data

The historical data trend for OncoCyte's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PS Ratio
Premium Member Only Premium Member Only Premium Member Only - - - - 125.79

OncoCyte Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 955.00 139.00 125.79 167.42 110.38

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

OncoCyte PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's PS Ratio distribution charts can be found below:

* The bar in red indicates where OncoCyte's PS Ratio falls into.



OncoCyte PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

OncoCyte's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=3.40/0.052
=65.38

OncoCyte's Share Price of today is $3.40.
OncoCyte's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


OncoCyte  (NAS:OCX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


OncoCyte PS Ratio Related Terms

Thank you for viewing the detailed overview of OncoCyte's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte Business Description

OncoCyte logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, the company also developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through United States and it earns revenue from the sale of diagnostic tests.
Executives
Carter Jennifer L. director C/O DFP SPONSOR LLC 780 THIRD AVENUE, 37TH FLOOR NEW YORK NY 10017
Kalajian Tony T officer: Sr.VP/Chief Accounting Officer 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Parker Albert P officer: Chief Operating Officer C/O ONCOCYTE CORPORATION 1010 ATLANTIC AVENUE, SUITE 102 ALAMEDA CA 94501
Levine Mitchell S officer: Chief Financial Officer ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO CA 94111
Andrews Ronald Asbury director, officer: Chief Executive Officer 5791 VAN ALLEN WAY CARLSBAD CA 92008
Redmond Cavan M. director 5 GIRALDA FARMS MADISON NJ 07940
Griffith Melinda director 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Arno Andrew director C/O MERRIMAN CURHAN FORD GROUP, INC. 600 CALIFORNIA STREET, 9TH FLOOR SAN FRANCISCO CA 94108
Kingsley Alfred D director 150 E 57TH STREET NEW YORK NY 10022
Last Andrew J. director 3420 CENTRAL EXPRESSWAY SANTA CLARA CA 95051
Broadwood Capital Inc 10 percent owner 724 FIFTH AVENUE 9TH FLOOR NEW YORK NY 10019
Broadwood Partners, L.p. 10 percent owner BROADWOOD CAPITAL INC. 724 FIFTH AVENUE, 9TH FLOOR NEW YORK NY 10019
Bradsher Neal C 10 percent owner PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: BRADSHER NEAL C a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Ross Douglas T. officer: Chief Medical Officer 15 CUSHING IRVINE CA 92618
Sundar Padma officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501

OncoCyte Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)